Both in Pharmaceuticals
Aclaris Therapeutics vs PUMA BIOTECHNOLOGY
Over the past year ACRS returned +69.4% and PBYI returned +104.8%; their daily moves had a correlation of 0.31.
ACRS +69.4% PBYI +104.8%Growth of $1, one year, split-adjusted
| Metric | ACRS | PBYI |
|---|---|---|
| Price | $3.97 | $10.57 |
| Market cap | $583.6M | $545.6M |
| Today | −0.63% | +0.28% |
| 1 month | −10.1% | +7.4% |
| 6 months | −10.1% | +41.1% |
| Year to date | +31.7% | +77.6% |
| 1 year | +69.4% | +104.8% |
| Revenue growth (YoY) | −8.3% | +7.8% |
| Gross margin | 86.6% | 77.9% |
| Net margin | −1320.1% | 14.5% |
| P/E (TTM) | — | 20.4× |
| Price / sales | 71.0× | 2.4× |
| Net cash | $91.6M | $93.9M |
| Dividend yield | — | — |
| Volatility (60d) | 75.5% | 43.5% |
| Short % of float | 12.4% | 11.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).